Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Heterogenous mitochondrial ultrastructure and metabolism of human glioblastoma cells : differences between stem-like and differentiated cancer cells in response to chemotherapy
Authors:ID Bogataj, Urban (Author)
ID Novak, Metka (Author)
ID Galun, Simona Katrin (Author)
ID Fon Tacer, Klementina (Author)
ID Vittori, Miloš (Author)
ID Noorden, Cornelis J. F. van (Author)
ID Breznik, Barbara (Author)
Files:URL URL - Source URL, visit https://dx.doi.org/10.2478/raon-2025-0056
 
.pdf PDF - Presentation file, download (1,35 MB)
MD5: 3669243B488524998344B4F4FB11041F
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo NIB - National Institute of Biology
Abstract:Background[:] Glioblastoma stem-like cells (GSCs) contribute to the resistance of glioblastoma (GBM) tumors to standard therapies. The background of the resistance of GSCs to the chemotherapeutic agent temozolomide is not yet fully understood in the context of cellular metabolism and the role of mitochondria. The aim of this study was to perform a detailed ultrastructural characterization of the mitochondria of GSCs prior and post temozolomide exposure and to compare it to differentiated GBM cells. Materials and methods[:] Patient-derived and established GBM cell lines were used for the study. The ultrastructure of the mitochondria of the examined cell lines was assessed by transmission electron microscopy. The microscopic analysis was complemented and compared by an analysis of cell metabolism using Seahorse extracellular flux analysis. Results[:] We found that the metabolic profile of GSCs is quiescent and aerobic. Their elongated mitochondria with highly organized cristae are indicating increased biogenesis and mitochondrial fusion and corresponds to a more oxidative phosphorylation (OXPHOS)-dependent metabolism. The metabolism of GSCs is dependent on OXPHOS and there are no changes in defective mitochondria fraction after the treatment with temozolomide. In contrast, differentiated GBM cells with fragmented mitochondria, which have less organized cristae, are more energetic and glycolytic. Temozolomide treatment induced ultrastructural mitochondrial damage in differentiated GBM cells. Conclusions[:] We demonstrated differences in mitochondrial ultrastructure and cellular metabolism between GSCs and differentiated GBM cells in response to temozolomide, suggesting that mitochondria play an important role in the resistance of GSCs to temozolomide. This study provides a basis for further studies addressing GSC chemotherapy resistance in the context of mitochondrial structure and function.
Keywords:glioblastoma, mitochondria, metabolism, chemotherapy, stem cells
Publication status:Published
Publication version:Version of Record
Publication date:27.10.2025
Year of publishing:2025
PID:20.500.12556/DiRROS-24389 New window
UDC:616-006
ISSN on article:1581-3207
DOI:10.2478/raon-2025-0056 New window
COBISS.SI-ID:258580739 New window
Note:Nasl. z nasl. zaslona; Soavtorji: Metka Novak, Simona Katrin Galun, Klementina Fon Tacer, Milos Vittori, Cornelis J.F. Van Noorden, Barbara Breznik; Članek v PDF formatu obsega 15 str.; Opis vira z dne 26. 11. 2025; Online first: 27. Oct. 2025;
Publication date in DiRROS:26.11.2025
Views:98
Downloads:50
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Publisher:Association of Radiology and Oncology
ISSN:1581-3207
COBISS.SI-ID:784507 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0245-2019
Name:Ekotoksiologija, toksikološka genomika in karcinogeneza

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J3-4504-2022
Name:Z vizualizacijo mikrookolja glioblastoma do boljše terapije

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:BI-US/22-24-007-2022
Name:Vloga proteinov MAGE v glioblastomskih matičnih celicah in odpornosti na terapijo: ali nam lahko znanje o biologiji matičnih celicah pomaga zdraviti na terapijo odporne možganske tumorje?

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J3-2526-2020
Name:Razkrivanje niše matičnih glioma celic v iskanju novih terapevtskih ciljev pri bolnikih z glioblastomom

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:BI-US/24-26-022-2024
Name:Izkoriščanje proteinov MAGE za boj proti odpornosti agresivnih tumorjev na zdravljenje

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:N3-0394-2025
Name:Dinamika organoidov za boj proti terapevtski odpornosti glioblastoma

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:NC-25002-2025
Name:Ciljanje glioblasomskih celic v mikrookolju tumorja s kombinacijo obsevanja in selektivnih inhibitorjev metaloproteaz

Funder:Other - Other funder or multiple funders
Project number:RR200059
Name:Cancer Prevention and Research Institute of Texas Scholar

Funder:Other - Other funder or multiple funders
Project number:22-0321
Name:Foundation for Prader-Willi Syndrome Research Grant
Acronym:FPWR

Funder:EC - European Commission
Project number:101079113
Name:TWINNING FOR EXCELLENCE TO STRATEGICALLY ADVANCE RESEARCH IN CARCINOGENESIS AND CANCER
Acronym:CutCancer

Funder:EC - European Commission
Project number:101136552
Name:SPatial Analysis of Cancer Evolution in the Tumour Immune MicroEnvironment
Acronym:SPACETIME

Funder:ARIS - Slovenian Research and Innovation Agency
Funding programme:Young Researcher Grant

Funder:Fulbright Fellowship Scholar

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:glioblastom, mitohondriji, metabolizem, kemoterapija, matične celice


Back